New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
06:14 EDTPBYIPuma Biotechnology 980K share Secondary priced at $122.50
The deal size was increased to 980k shares from 816k shares. BofA/Merrill, Citigroup and Leerink acted as joint book running managers for the offering.
News For PBYI From The Last 14 Days
Check below for free stories on PBYI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
07:12 EDTPBYIPuma Biotechnology neratinib use unlikely to be limited, says Citigroup
Although Puma's Neratinib breast cancer drug was enriched for high risk HER2+ patients during a recent trial, Citigroup does not expect its use to be restricted to high risk women. The firm keeps a $292 price target and Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use